TY - JOUR
T1 - Effect of RAAS inhibition on the incidence of cancer and cancer mortality in patients with glomerulonephritis
AU - Chin, Ho Jun
AU - Oh, Se Won
AU - Goo, Ho Suk
AU - Oh, Jieun
AU - Noh, Jung Woo
AU - Cho, Jong Tae
AU - Na, Ki Young
AU - Kim, Suhnggwon
AU - Chae, Dong Wan
PY - 2011/1
Y1 - 2011/1
N2 - Angiotensin II type 1 receptor blocker (ARB), which is frequently prescribed in patients with glomerulonephritis (GN), is suggested to increase the risk of cancer. We registered 3,288 patients with renal biopsy and analyzed the relationship between the use of reninangiotensin-aldosterone system (RAAS) blockade and the incidence of cancer or cancer mortality. After renal biopsy, cancer developed in 33 patients with an incidence rate of 1.0% (95% of CI for incidence: 0.7%-1.3%). There was no difference in the cancer incidence among the groups according to the use of angiotensin-converting enzyme inhibitors (ACEI) or ARB: 1.2% in the None (23/1960), 0.7% in the ARB-only (5/748), 0.4% in the ACEI-only (1/247), and 1.2% in the ACEI-ARB (4/333) (P = 0.487) groups. The cancer mortality was 2.1%, 0.4%, 0.0%, and 0.3% in None, ACEI-only, ARB-only, and ACEI-ARB group, respectively (P < 0.001). The risk of cancer mortality in patients with ARB was only 0.124 (0.034-0.445) compared to that of non-users of ARB by Cox's hazard proportional analysis. In conclusion, prescription of ACEI or ARB in patients with GN does not increase cancer incidence and recipients of ARB show rather lower rates of all-cause mortality and cancer mortality.
AB - Angiotensin II type 1 receptor blocker (ARB), which is frequently prescribed in patients with glomerulonephritis (GN), is suggested to increase the risk of cancer. We registered 3,288 patients with renal biopsy and analyzed the relationship between the use of reninangiotensin-aldosterone system (RAAS) blockade and the incidence of cancer or cancer mortality. After renal biopsy, cancer developed in 33 patients with an incidence rate of 1.0% (95% of CI for incidence: 0.7%-1.3%). There was no difference in the cancer incidence among the groups according to the use of angiotensin-converting enzyme inhibitors (ACEI) or ARB: 1.2% in the None (23/1960), 0.7% in the ARB-only (5/748), 0.4% in the ACEI-only (1/247), and 1.2% in the ACEI-ARB (4/333) (P = 0.487) groups. The cancer mortality was 2.1%, 0.4%, 0.0%, and 0.3% in None, ACEI-only, ARB-only, and ACEI-ARB group, respectively (P < 0.001). The risk of cancer mortality in patients with ARB was only 0.124 (0.034-0.445) compared to that of non-users of ARB by Cox's hazard proportional analysis. In conclusion, prescription of ACEI or ARB in patients with GN does not increase cancer incidence and recipients of ARB show rather lower rates of all-cause mortality and cancer mortality.
KW - Angiotensin II Type 1 Receptor Blockers
KW - Glomerulonephritis
KW - Neoplasms
UR - http://www.scopus.com/inward/record.url?scp=78650772778&partnerID=8YFLogxK
U2 - 10.3346/jkms.2011.26.1.59
DO - 10.3346/jkms.2011.26.1.59
M3 - Article
C2 - 21218031
AN - SCOPUS:78650772778
SN - 1011-8934
VL - 26
SP - 59
EP - 66
JO - Journal of Korean medical science
JF - Journal of Korean medical science
IS - 1
ER -
